Browse result page of AntiTbPdb
The total number entries retrieved from this search are 51
| ID | Name | Sequence | N-Terminal Modification | C-Terminal Modification | Chemical Modification | Linear/Cyclic | Length | Chirality | Nature | Source | Origin | Species | Strain | Inhibition Concentration | In vitro/ In vivo | Cell Line | Intracellular Inhibition | Cytotoxicity | Animal Model | Effective Dose in model organism | Immune Responce | Mechanism of Action | Target | Combination Therapy | Other Activities | Year of Publication | Pubmed ID/ Patent No. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| antitb_1001 | Polydim-I | AVAGEKLWLLPHLLKMLLTPTP | Free | Free | None | Linear | 22 | L | Amphipathic | Natural | Isolated from the venom of the Neotropical wasp Polybia dimorpha | Mycobacterium abscessus subsp. massiliense | Mycobacterium abscessus subsp. massiliense isolates GO 01, GO 06, GO 07, GO 08, GO 13, and GO 18, CRM0020 (Mycobacterium abscessus subsp. massiliense), and ATCC19977 (Mycobacterium abscessus subsp. abscessus) | MIC = 60.8 μg/mL | Both | Peritoneal macrophages, J774 macrophages cells, human red blood cells | Treatment of infected macrophages with 7.6 μg/mL of Polydim-I decreased approximately 50% of the bacterial load | Non-cytotoxic, 10% cytotoxicity on J774 cells at concentrations above 121.6 μg/mL (10%) and concentrations up to 121.6 μg/mL presented less than 2.5% of hemolytic activity | 6 to 8 weeks old BALB/c and IFN-γKO (Knockout) female mice | 2 mg/kg/mLW shows 90% reduction in bacterial load | NA | Cell wall disruption | Cell wall | None | NA | 2016 | 26930596 |
| antitb_1123 | PR-39 | RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP | Free | Amidation | None | Linear | 39 | L | Amphipathic | Natural | Isolated from porcine leucocytes | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv (ATCC 25618) | 50 mg/L causes 80% growth inhibition of m. tuberculosis H37Rv | In vitro | None | NA | NA | None | NA | NA | Disrupt the membrane architecture | Cell envelope | None | Antibacterial against salmonella, staphylococcus and neisseria | 2001 | 11328767 |
| antitb_1124 | PR-39 | RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP | Free | Amidation | None | Linear | 39 | L | Amphipathic | Natural | Isolated from porcine leucocytes | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv (ATCC 25618) | MIC50 = 17 ± 9 mg/L | In vitro | None | NA | NA | None | NA | NA | Disrupt the membrane architecture | Cell envelope | None | Antibacterial against salmonella, staphylococcus and neisseria | 2001 | 11328767 |
| antitb_1125 | PR-39 | RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP | Free | Amidation | None | Linear | 39 | L | Amphipathic | Natural | Isolated from porcine leucocytes | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv (ATCC 25618) | 6.25 mg/L causes 30% growth inhibition of M. tuberculosis H37Rv | In vitro | None | NA | NA | None | NA | NA | Disrupt the membrane architecture | Cell envelope | None | Antibacterial against salmonella, staphylococcus and neisseria | 2001 | 11328767 |
| antitb_1126 | PR-39 | RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP | Free | Amidation | None | Linear | 39 | L | Amphipathic | Natural | Isolated from porcine leucocytes | Mycobacterium tuberculosis | Mycobacterium tuberculosis E1380/94 MDR (Isoniazid, rifampicin, streptomycin, ethambutol) strain | 50 mg/L causes 39 % growth inhibition | In vitro | None | NA | NA | None | NA | NA | Disrupt the membrane architecture | Cell envelope | None | Antibacterial against salmonella, staphylococcus and neisseria | 2001 | 11328767 |
| antitb_1127 | PR-39 | RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP | Free | Amidation | None | Linear | 39 | L | Amphipathic | Natural | Isolated from porcine leucocytes | Mycobacterium tuberculosis | Mycobacterium tuberculosis E1380/94 MDR (Isoniazid, rifampicin, streptomycin, ethambutol) strain | MIC50 = 93 ± 12 mg/L | In vitro | None | NA | NA | None | NA | NA | Disrupt the membrane architecture | Cell envelope | None | Antibacterial against salmonella, staphylococcus and neisseria | 2001 | 11328767 |
| antitb_1128 | PR-39 | RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP | Free | Amidation | None | Linear | 39 | L | Amphipathic | Natural | Isolated from porcine leucocytes | Mycobacterium tuberculosis | Mycobacterium tuberculosis P34/95 MDR (isoniazid and rifampicin) strain | 50 mg/L causes 49 % growth inhibition | In vitro | None | NA | NA | None | NA | NA | Disrupt the membrane architecture | Cell envelope | None | Antibacterial against salmonella, staphylococcus and neisseria | 2001 | 11328767 |
| antitb_1129 | PR-39 | RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP | Free | Amidation | None | Linear | 39 | L | Amphipathic | Natural | Isolated from porcine leucocytes | Mycobacterium tuberculosis | Mycobacterium tuberculosis #894-D11 streptomycin resistant strain | 50 mg/L causes 80% growth inhibition | In vitro | None | NA | NA | None | NA | NA | Disrupt the membrane architecture | Cell envelope | None | Antibacterial against salmonella, staphylococcus and neisseria | 2001 | 11328767 |
| antitb_1130 | PR-39 | RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP | Free | Amidation | None | Linear | 39 | L | Amphipathic | Natural | Isolated from porcine leucocytes | Mycobacterium tuberculosis | BTB 98-492 drug suspectible swedish clinical isolate | 50 mg/L causes 80% growth inhibition | In vitro | None | NA | NA | None | NA | NA | Disrupt the membrane architecture | Cell envelope | None | Antibacterial against salmonella, staphylococcus and neisseria | 2001 | 11328767 |
| antitb_1131 | PR-39 | RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP | Free | Amidation | None | Linear | 39 | L | Amphipathic | Natural | Isolated from porcine leucocytes | Mycobacterium smegmatis | Mycobacterium smegmatis (ATCC 19420) | IC90 = 50mg/L | In vitro | None | NA | NA | None | NA | NA | Disrupt the membrane architecture | Cell envelope | None | Antibacterial against salmonella, staphylococcus and neisseria | 2001 | 11328767 |
| antitb_1140 | LLKKK-18 | KEFKRIVKRIKKFLRKL | Free | Free | None | Linear | 17 | L | Amphipathic | Protein Derived | Variant of LL-37 | Mycobacterium smegmatis | Mycobacterium smegmatis mc2155 (ATCC 700084) | 25 μg of LLKKK-18/ml killed >80% of M. smegmatis after 24 h | In vitro | RAW264.7 | No significant reduction in intracellular survival of M. smegmatis was observed | No significant reduction in cell viability upto 25 μg/ml | None | NA | NA | Permeabilization of the bacterial cell membrane | Cell envelope | None | None | 2013 | 23689720 |
| antitb_1141 | LLKKK-18 | KEFKRIVKRIKKFLRKL | Free | Free | None | Linear | 17 | L | Amphipathic | Protein Derived | Variant of LL-38 | Mycobacterium smegmatis | Mycobacterium smegmatis mc2155 (ATCC 700084) | 0.5 ppm of NP-1 combined with 1 μg/ml of LLKKK-18 kills 50% of M. smegmatis | In vitro | RAW264.7 | NP-1 in combination with LLKKK-18 kills 65% of mycobacteria compared to NP-1 or LLKKK-18 alone. | No significant reduction in cell viability either treating alone or combination | None | NA | NA | Permeabilization of the bacterial cell membrane | Cell envelope | AgNPs synthesiszed only in the presence of a plant Alstonia macrophylla (NP-1). | None | 2013 | 23689720 |
| antitb_1142 | LLKKK-18 | KEFKRIVKRIKKFLRKL | Free | Free | None | Linear | 17 | L | Amphipathic | Protein Derived | Variant of LL-39 | Mycobacterium smegmatis | Mycobacterium smegmatis mc2155 (ATCC 700084) | 0.5 ppm of NP-2 combined with 1 μg/ml of LLKKK-18 kills 89% of M. smegmatis | In vitro | RAW264.7 | No significant reduction | No significant reduction in cell viability either treating alone or combination | None | NA | NA | Permeabilization of the bacterial cell membrane | Cell envelope | AgNPs synthesiszed only in the presence of a fungal Trichoderma sp. (NP-2). | None | 2013 | 23689720 |
| antitb_1143 | LLKKK-18 | KEFKRIVKRIKKFLRKL | Free | Free | None | Linear | 17 | L | Amphipathic | Protein Derived | Variant of LL-40 | Mycobacterium marinum | Mycobacterium marinum (ATCC 927) | IC 90 = 1 μg/ml | In vitro | RAW264.7 | Moderate killing was observed | No significant reduction in cell viability either treating alone or combination | None | NA | NA | Permeabilization of the bacterial cell membrane | Cell envelope | None | None | 2013 | 23689720 |
| antitb_1778 | Peptide-22 | KL-Tic-Oic-K-Tic-Oic-F-Tic-Oic-K-Tic-Oic-F-Tic-Oic-K-Tic-Oic-KR | Free | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 21 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 30 µM or 93 µg/mL | Both | RBC | NA | 63 % hemolytic activity at 100 µM peptide | mouse skin wound healing model | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1779 | Peptide-23 | GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 10 µM or 24 µg/mL | Both | RBC | NA | 14 % hemolytic activity at 100 µM peptide | mouse skin wound healing model | Acute toxicity was observed at dose of 125 mg/kg | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1780 | Peptide-24 | GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK | Acetylation | Addition of -CONH-CH2-CH2-NH2 | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 10 µM or 25 µg/mL | Both | NA | NA | Not tested | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1781 | Peptide-25 | GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK | Acetylation | Addition of CONH-CH2-CH2-CH2-NH2 | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 10 µM or 25 µg/mL | Both | NA | NA | Not tested | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1782 | Peptide-26 | GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK | Free | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 10 µM or 24 µg/mL | Both | RBC | NA | 33.4 % and 14.3% hemolytic activity at 100 µM and 25 µM peptide respectively | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1783 | Peptide-27 | KL-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK | Free | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 3 µM or 7.5 µg/mL | Both | RBC | NA | 43.6 % and 24.9 % hemolytic activity at 100 µM and 25 µM peptide respectively | mouse skin wound healing model | No toxicity observed at 25 mg/kg for 6 days | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1784 | Peptide-28 | F-Tic-Oic-K-Tic-Oic-F-Tic-Oic-K-Tic-KKKK | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 15 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 30 µM or 66 µg/mL | Both | RBC | NA | 86.8 % and 50 % hemolytic activity at 100 µM and 25 µM peptide respectively | mouse skin wound healing model | No toxicity observed at 25 mg/kg for 6 days | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1785 | Peptide-29 | GABA-F-Tic-Oic-GABA-K-Tic-Oic-GABA-F-Tic-Oic-GABA-K-Tic-KKKK | Acetylation | Amidation | GABA = Gama aminobutyric acid, Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 10 µM or 28 µg/mL | Both | RBC | NA | 10.8 % and 1 % hemolytic activity at 100 µM and 25 µM peptide respectively | mouse skin wound healing model | No toxicity observed at 25 mg/kg for 6 days | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1786 | Peptide-30 | G-Tic-Oic-K-Tic-Oic-G-Tic-Oic-K-Tic-KKKK | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 15 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 3 µM or 6 µg/mL | Both | RBC | NA | 26.7 % and 9.2 % hemolytic activity at 100 µM and 25 µM peptide respectively | mouse skin wound healing model | No toxicity observed at 25 mg/kg for 6 days | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1787 | Peptide-31 | GF-Oic-GK-Oic-GF-Oic-GKKKKK | Acetylation | Amidation | Oic = Octahydroindolecarboxylic acid | Linear | 15 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 100 µM or 180 µg/mL | Both | RBC | NA | 5.9 % and 3.2 % hemolytic activity at 100 µM and 25 µM peptide respectively | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1788 | Peptide-32 | GF-Tic-GK-Tic-GF-Tic-GK-Tic-KKKK | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid | Linear | 15 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 30 µM or 60 µg/mL | Both | RBC | NA | 6 % and 4.9 % hemolytic activity at 100 µM and 25 µM peptide respectively | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1789 | Peptide-33 | GF-Tic-G-GK-Tic-G-GF-Tic-G-GK-Tic-KKKK | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 30 µM or 66 µg/mL | Both | RBC | NA | 5.70 % and 3.80 % hemolytic activity at 100 µM and 25 µM peptide respectively | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1790 | Peptide-34 | GF-G-Oic-GK-G-Oic-GF-G-Oic-GK-G-KKKK | Acetylation | Amidation | Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 100 µM or 200 µg/mL | Both | RBC | NA | 3.3 % and 3.30 % hemolytic activity at 100 µM and 25 µM peptide respectively | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1791 | Peptide-35 | GF-F-Oic-GK-F-Oic-GF-F-Oic-GK-F-KKKK | Acetylation | Amidation | Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 10 µM or 24 µg/mL | Both | RBC | NA | 27.30 % and 8.9 % hemolytic activity at 100 µM and 25 µM peptide respectively | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1792 | Peptide-36 | βAla-F-Tic-Oic-βAla-K-Tic-Oic-βAla-F-Tic-Oic-βAla-K-Tic-KKKK | Acetylation | Amidation | βAla= beta-alanine, Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 1 µM or 2.5 µg/mL | Both | RBC | NA | 24.4 % and 7.4 % hemolytic activity at 100 µM and 25 µM peptide respectively | mouse skin wound healing model | Acute toxicity was observed at dose of 125 mg/kg | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1793 | Peptide-37 | Ahx-F-Tic-Oic-Ahx-K-Tic-Oic-Ahx-F-Tic-Oic-Ahx-K-Tic-KKKK | Acetylation | Amidation | Ahx = 6-amino hexanoic acid, Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 3 µM or 8.1 µg/mL | Both | RBC | NA | 44.7 % and 26.6 % hemolytic activity at 100 µM and 25 µM peptide respectively | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1794 | Peptide-38 | F-Tic-Oic-K-Tic-Oic-F-Tic-Oic-K-Tic-KKKKKK | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 17 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 3 µM or 7.5 µg/mL | Both | RBC | NA | 41.3 % and 33.5 % hemolytic activity at 100 µM and 25 µM peptide respectively | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1795 | Peptide-39 | GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKKK | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 3 µM or 7.8 µg/mL | Both | RBC | NA | 24.9 % and 18.9 % hemolytic activity at 100 µM and 25 µM peptide respectively | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1796 | Peptide-40 | GABA-F-Tic-Oic-GABA-K-Tic-Oic-GABA-F-Tic-Oic-GABA-K-Tic-KKKKK | Acetylation | Amidation | GABA = Gama aminobutyric acid, Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 3 µM or 8.1 µg/mL | Both | RBC | NA | 29.7 % and 10.5 % hemolytic activity at 100 µM and 25 µM peptide respectively | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1797 | Peptide-41 | GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-Orn-Orn-Orn-Orn | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid, Orn = Ornithine | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 10 µM or 24 µg/mL | Both | NA | NA | Not tested | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1798 | Peptide-42 | G-Fpa-Tic-Oic-GK-Tic-Oic-G-Fpa-Tic-Oic-GK-Tic-KKKK | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid, Fpa = 4-fluorophenylalanine | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 3 µM or 7.5 µg/mL | Both | NA | NA | Not tested | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1799 | Peptide-43 | GF-Tic-Oic-G-Orn-Tic-Oic-GF-Tic-Oic-G-Orn-Tic-Orn-Orn-Orn-Orn | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid, Orn = Ornithine | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 10 µM or 24 µg/mL | Both | NA | NA | Not tested | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1800 | Peptide-44 | GF-Tic-Oic-GK-Tic-Oic-GF-Tic-Oic-GK-Tic-KKKK | Biotinylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 10 µM or 26 µg/mL | Both | NA | NA | Not tested | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1801 | Peptide-45 | GF-Tic-Oic-G-Dpr-Tic-Oic-GF-Tic-Oic-G-Dpr-Tic-Dpr-Dpr-Dpr-Dpr | Acetylation | Amidation | Dpr = diaminopropionic acid, Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 100 µM or 220 µg/mL | Both | NA | NA | Not tested | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1802 | Peptide-46 | βAla-Fpa-Tic-Oic-βAla-Dpr-Tic-Oic-βAla-Fpa-Tic-Oic-βAla-Dpr-Tic-Dpr-Dpr-Dpr-Dpr | Acetylation | Amidation | βAla = beta-alanine, Fpa, 4-fluorophenylalanine, Dpr = diaminopropionic acid, Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 100 µM or 228 µg/mL | Both | NA | NA | Not tested | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1803 | Peptide-47 | G-f-Tic-Oic-GK-Tic-Oic-G-f-Tic-Oic-GK-Tic-KKKK | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | Mix | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 10 µM or 24 µg/mL | Both | NA | NA | Not tested | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1804 | Peptide-48 | GF-Tic-Oic-G-k-Tic-Oic-GF-Tic-Oic-G-k-Tic-KKKK | Acetylation | Amidation | Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | Mix | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 10 µM or 24 µg/mL | Both | NA | NA | Not tested | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1805 | Peptide-49 | G-Nph-Tic-Oic-GK-Tic-Oic-G-Nph-Tic-Oic-GK-Tic-KKKK | Acetylation | Amidation | Nph = 4-nitrophenylalanine, Tic = tetrahydroisoquinolinecarboxylic acid, Oic = Octahydroindolecarboxylic acid | Linear | 19 | L | Amphipathic, Hydrophobic | Synthetic | NA | Mycobacterium ranae | Mycobacterium ranae (ATCC 110) | MIC = 10 µM or 25 µg/mL | Both | NA | NA | Not tested | NA | NA | Stimulate innate immune system | NA | NA | NA | Antibacterial (Salmonella typhimurium (ATCC 13311), Staphylococcus aureus methicillin/gentamicin/tetrac+AB20ycline resistant (ATCC 33592), Bacillus subtillis (ATCC 43223)) | 2007 | 17547385 |
| antitb_1861 | Anoplin | GLLKRIKTLL | Addition of octanoic acid (C8H16O2) | Amidation | None | Linear | 10 | L | Amphipathic | Synthetic | Anlogue of Anoplin | Mycobacterium smegmatis | Mycobacterium smegmatis mc2 156 | MIC = 200 μg/mL | In vitro | RBC | NA | Non toxic to erythrocytes | NA | NA | NA | NA | NA | NA | Antifungal (C. parapsilosis) and Antibacterial (Escherichia coli DH5a, Pseudomonas aeruginosa PAO, and Zymomonas mobilis ATCC 10988; Gram-positive bacteria: Bacillus subtilis DELTA) | 2016 | 27862650 |
| antitb_1862 | Anoplin | GLLKRIKTLL | Addition of decanoic acid (C10H20O2) | Amidation | None | Linear | 10 | L | Amphipathic | Synthetic | Anlogue of Anoplin | Mycobacterium smegmatis | Mycobacterium smegmatis mc2 157 | MIC = 200 μg/mL | In vitro | RBC | NA | Non toxic to erythrocytes | NA | NA | NA | NA | NA | NA | Antifungal (C. parapsilosis) and Antibacterial (Escherichia coli DH5a, Pseudomonas aeruginosa PAO, and Zymomonas mobilis ATCC 10988; Gram-positive bacteria: Bacillus subtilis DELTA) | 2016 | 27862650 |
| antitb_1863 | Anoplin | GLLKFIKKLL | Free | Amidation | None | Linear | 10 | L | Amphipathic | Synthetic | Anlogue of Anoplin | Mycobacterium smegmatis | Mycobacterium smegmatis mc2 158 | MIC = 15 μg/mL | In vitro | RBC | NA | Non toxic to erythrocytes | NA | NA | NA | NA | NA | NA | Antifungal (C. parapsilosis) and Antibacterial (Escherichia coli DH5a, Pseudomonas aeruginosa PAO, and Zymomonas mobilis ATCC 10988; Gram-positive bacteria: Bacillus subtilis DELTA) | 2016 | 27862650 |
| antitb_1864 | Anoplin | KLLKFIKKLL | Free | Amidation | None | Linear | 10 | L | Amphipathic | Synthetic | Anlogue of Anoplin | Mycobacterium smegmatis | Mycobacterium smegmatis mc2 159 | MIC = 15 μg/mL | In vitro | RBC | NA | Non toxic to erythrocytes | NA | NA | NA | NA | NA | NA | Antifungal (C. parapsilosis) and Antibacterial (Escherichia coli DH5a, Pseudomonas aeruginosa PAO, and Zymomonas mobilis ATCC 10988; Gram-positive bacteria: Bacillus subtilis DELTA) | 2016 | 27862650 |
| antitb_1865 | Anoplin | RLLKFIKKLL | Free | Amidation | None | Linear | 10 | L | Amphipathic | Synthetic | Anlogue of Anoplin | Mycobacterium smegmatis | Mycobacterium smegmatis mc2 160 | MIC = 20 μg/mL | In vitro | RBC | NA | Non toxic to erythrocytes | NA | NA | NA | NA | NA | NA | Antifungal (C. parapsilosis) and Antibacterial (Escherichia coli DH5a, Pseudomonas aeruginosa PAO, and Zymomonas mobilis ATCC 10988; Gram-positive bacteria: Bacillus subtilis DELTA) | 2016 | 27862650 |
| antitb_1866 | Anoplin | GLLKFIKKLL | Addition of octanoic acid (C8H16O2) | Amidation | None | Linear | 10 | L | Amphipathic | Synthetic | Anlogue of Anoplin | Mycobacterium smegmatis | Mycobacterium smegmatis mc2 161 | MIC = 5 μg/mL | In vitro | RBC | NA | Non toxic to erythrocytes | NA | NA | NA | NA | NA | NA | Antifungal (C. parapsilosis) and Antibacterial (Escherichia coli DH5a, Pseudomonas aeruginosa PAO, and Zymomonas mobilis ATCC 10988; Gram-positive bacteria: Bacillus subtilis DELTA) | 2016 | 27862650 |
| antitb_1867 | Anoplin | GLLKFIKKLL | Addition of decanoic acid (C10H20O2) | Amidation | None | Linear | 10 | L | Amphipathic | Synthetic | Anlogue of Anoplin | Mycobacterium smegmatis | Mycobacterium smegmatis mc2 162 | MIC = 5 μg/mL | In vitro | RBC | NA | Non toxic to erythrocytes | NA | NA | NA | NA | NA | NA | Antifungal (C. parapsilosis) and Antibacterial (Escherichia coli DH5a, Pseudomonas aeruginosa PAO, and Zymomonas mobilis ATCC 10988; Gram-positive bacteria: Bacillus subtilis DELTA) | 2016 | 27862650 |
| antitb_1868 | Anoplin | GLLKFIKKLL | Addition of dodecanoic acid (C12H24O2) | Amidation | None | Linear | 10 | L | Amphipathic | Synthetic | Anlogue of Anoplin | Mycobacterium smegmatis | Mycobacterium smegmatis mc2 163 | MIC = 5 μg/mL | In vitro | RBC | NA | Non toxic to erythrocytes | NA | NA | NA | NA | NA | NA | Antifungal (C. parapsilosis) and Antibacterial (Escherichia coli DH5a, Pseudomonas aeruginosa PAO, and Zymomonas mobilis ATCC 10988; Gram-positive bacteria: Bacillus subtilis DELTA) | 2016 | 27862650 |